On January 20, 2021, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. announced that the first Fc fusion protein drug targeting human CD47 (Project No.: IMM01) in China, expanding new indications (AML and MDS) and obtaining NMPA clinical trial research license. This is another milestone of ImmuneOnco's further research and development of CD47 target drugs, and further establishes ImmuneOnco's leading echelon position in the research and development of CD47 target drugs.

"We are very glad to see that our IMM01 project has obtained the NMPA clinical trial research license to expand new indications. The phase I clinical trial of IMM01 project for lymphoma (HL & NHL) is coming to an end, and has obtained exciting clinical manifestations! We think that this is due to the difference design of IMM01 itself. IMM01 does not bind to human red blood cells at all. It avoids "antigenic sink" and does not appear ADA. It has small molecule (half of antibody). It has good tissue permeability and bioavailability. Therefore, we believe that IMM01 will have great advantages in clinical development. " Dr. Tian Wenzhi, founder and chairman of ImmuneOnco, is full of confidence in the clinical trial of IMM01. "We hope to further expand the research on new indications and combination drugs of IMM01 project in the future, so as to benefit more subjects. We will accelerate the clinical trial research of IMM01 and accelerate the listing of IMM01, so as to benefit cancer patients as soon as possible. ".